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Abstract
Background: There are proposed various methods of treatment of articular syndrome associated with chronic tonsillitis (CT), however, in most cases 
the desired effect is not reached. The insufficient effectiveness of the treatment measures is, to a certain extent, subject to the underestimation of the 
immunogenetic role of the etiologic and pathogenetic character of these diseases. Recent years yielded obvious results in studying the correlation between 
the disease and the histocompatibility complex antigens – HLA (Human Leukocyte Antigens). At the foundation of the complex is the phenomenon of its 
predisposition to various diseases. In the curative approach of chronic tonsillitis, the presence of certain classes of HLA complex genes indicate the need 
for an early aggressive therapy. It deeply involves into the disease pathogenesis, coding the therapy evolution, prognosis and effects. In order to evaluate 
the impact of HLA class I antigenic determinants (A and B) on the clinical presentation, evolution and treatment strategy in patients with decompensated 
chronic tonsillitis associated with the articular syndrome (PSRA or ARF), we observed 101 adult patients aged 16-60 years, clinically and instrumentally 
diagnosed with decompensated chronic tonsillitis (CT): 50 patients had received conservative treatment and 51 patients were treated surgically.
Conclusions: The study of the major antigens has not found an association of HLA class I (A, B) with ARF and rheumatic heart disease (RHD).
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According to The American Academy of Otolaryn-
gology - Head and Neck Surgery, chronic tonsillitis (CT) 
is: an entity unresponsive to medical therapy; which is 
associated with halitosis; with clinical presentation of re-
current tonsillitis (RT) at persons carrying beta hemolytic 
streptococcus class A (ΒHSA); with absence of adequate 
response to antimicrobial therapy and with surgery indi-
cation (tonsillectomy) [10].
Chronic inflammation of the tonsils is one of the most 
common otorhinolaryngology diseases. About 10-50% of 
people complain of symptoms of chronic tonsillitis [2, 3]. 
The study conducted among the population of the Repu-
blic of Moldova in 2008-2009 (1500 people were examined 
in 16 districts and 38 villages), found the most common 
disorders of the pharynx: CT and chronic pharyngitis. The 
authors introduced the term chronic amigdalo-pharyngitis in 
the daily use of doctors, which contributes to a better selection 
of patients for those treatments [1].
Determining the prevalence of CT was performed by 
examining a group of 1371 children (967 children from ur-
ban area and 404 children from rural area of the Republic of 
Moldova). CT prevalence in children is 7.7%, does not depend 
on sex, and is more common at the age of 12-13 years and in 
urban areas [4, 5]. 
ΒHSA infection complications are classified as non-
suppurative and suppurative. Acute rheumatic fever (ARF), 
post-streptococcal reactive arthritis (PSRA) and acute glo-
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occurring generally after 1-3 weeks after the beginning of 
ΒHSA infection.
PSRA is a clinical syndrome without diagnostic criteria 
and clear treatment recommendations [34]. PSRA was defined 
as a non-suppurative inflammatory arthritis in two or more 
joints, which develops during or shortly after a streptococcal 
infection, located remotely, at a patient without Jones criteria 
for ARF diagnosis [18, 34, 40]. 
Studies conducted among both children and adults pos-
tulated the relationship between streptococcal tonsillitis and 
PSRA [11,14]. According to some studies, PSRA occurs most 
often in young adults [13]. Recurrent, severe and prolonged 
arthritis are important PSRA characteristics at adults [11].
ARF is an autoimmune disease caused by gram-positive 
bacteria Streptococcus pyogenes after an untreated oropha-
ryngeal infection at children genetically susceptible. This 
multi-system disorder is characterized by involvment of heart, 
joints, central nervous system, subcutaneous tissue and skin, 
but, except the heart, the other organs are affected transiently 
[39, 41, 44, 45].
There is no “gold standard” and no specific test to diagno-
se ARF, therefore, the diagnosis is arbitrary and empirical, 
especially in adults over the age of 25 years [22, 33, 37]. The 
diagnosis criteria of ARF were developed and published by 
Jones TD in 1944 [27, 32, 37, 44, 45], and till now are ex-
tremely important in the diagnosis, study and management 
of this injury [37]. The changes and subsequent updates of 
ARF criteria, published in 1965, 1984, 1992 and 2002, have 
concretized and completed major manifestations, have sim-
plified minor occurences, have removed the ambiguity and 
have detailed all criteria, have underlined the importance of 
the preceding streptococcal infections with the purpose of 
appropriate diagnosis of the initial stroke, the recurrent stroke, 
and minimizing the overdiagnosis of this condition, especially 
in countries with reduced incidence of ARF [22, 27, 32, 33, 37].
PSRA treatment represents the impovement of arthritis 
symptoms and eradication of streptococcal infection by admi-
nistration of non-steroidal anti-inflammatories and antibiotics 
[41]. Early tonsillectomy is a viable treatment for patients with 
PSRA after strep throat [13]. According to the AHA, patients 
with PSRA are recommended to be under surveillance for 
several months and under echocardiographic monitoring 
in order to detect a possible further development of carditis, 
which may be atypical (“quiet”). One of the recommendations 
is the secondary prophylactic administration of antibiotics to 
patients with PSRA for up to 1 year and, if the carditis is not 
determined, prophylaxis may be interrupted. If the carditis 
is diagnosed, the patient is considered to have ARF and he 
must continue getting the long-drawn secondary prophylaxis 
treatment with antibiotics [14, 17, 18].
ARF treatment is performed in several directions, the most 
commonly used are [29, 41, 44]: the treatment of streptococcal 
infection with penicillin G, a first-line anti-inflammatory 
treatment with acetyl salicylic acid in uncomplicated cases 
and with corticosteroids in more severe cases.
ARF prophylaxis comprises several aspects: elimination 
of risk factors associated with ΒHSA, detection and proper 
treatment of throat infections with ΒHSA with penicillin G 
(primary prevention), detection of healthy carriers of strep 
that are treated as symptomatic patients (primary preventi-
on), prevention of complications, in particular of carditis, in 
patients with ARF (secondary prevention) [30, 31].
Effective treatment of tonsillitis with ΒHSA reduces the 
risk of ARF by approximately 80-90%, but ΒHSA remains 
present in the pharynx in about 10% of cases, even after a 
proper treatment [29].
There are proposed various methods of treatment of CT: 
conservative treatment (local, general, prophylactic) and 
surgery (tonsillectomy). But in most cases the desired effect 
is not achieved. In addition, at this stage doctors demonstrate 
an explainable prudence regarding tonsillectomy, especially in 
children, when the physiological function of these lymphoid 
organs is maximal [2, 3, 19, 46].
The low efficiency of treatment measures is conditioned, 
to some extent, by the underestimation of the immunogenetic 
role of the etiopathogenic appearance of CT. In recent decades 
there were obtained obvious results in studying the correlation 
between CT and MHC- HLA antigen [38].
According to several recent studies, CT pathogenesis is 
complicated and diverse. Ethiopatogenic links between CT 
and other intercurrent diseases are not established. Studying 
the level of correlation between local immunological disorders 
and systemic immune processes, phenomena that are at the 
base of the immune response in the development zone of an 
isolated inflammatory process is important, at least from two 
points of view. On the one hand, these results will complement 
the vision of CT pathogenesis, and on the other hand, would 
give new impetus for the pathogenic treatment, serving also 
as a basis to form a fair outcome [6].
CT diagnosis is extremely difficult because both the onset 
and progression of the disease do not show specific clinical 
signs. The most common clinical manifestations of CT are 
obstructive hypertrophy of the tonsils (HT) and / or RT [37]. 
CT symptoms (painful and discrete sensations in the throat, 
non-disclosed sore throat, dysphagia, dry cough, bad brea-
th, pharyngeal discomfort, sensation of a foreign body and 
discomfort in the throat, burning and dryness in the throat, 
low-grade fever, pain in the lymphatic submandibular nodes, 
pain in the joints) are also met in other diseases (pharyngitis, 
laryngitis, esophagitis, gastritis, sinusitis etc.) [6, 10, 37].
Therefore, CT diagnosis is based on a combination of 
clinical and laboratory data, and instrumental examinations.
The general algorithm of conduct in the diagnosis of CT 
includes: 1) collection of anamnesis (patient accusations, 
disease duration, angina incurred in the past, associated di-
seases), 2) clinical objective examination (local signs of CT, 
changes in the joints, changes in the cardiovascular, kidney 
systems), 3) paraclinic laboratory tests: general analysis of 
blood, urine summary, electrocardiogram, biochemical exa-
mination of the blood (bilirubin, alanine aminotransferase, as-
partate aminotransferase, thymol test), inflammation samples 
(ESR, fibrinogen, C-reactive protein (CRP)), serology tests 
(ASLO), the examination of pharyngeal superficial exsudate, 
obtained from pads or fine needle aspiration (being significant 
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the presence of ΒHSA) and antibioticograma, consultation of 
an ENT doctor, pediatrician, rheumatologist, nephrologist and 
/ or urologist, stomatologist [3, 7, 12, 16, 19 32].
Although the risk of infection depends on environmental 
conditions (exposure, season, geographical area) and indivi-
dual variables (age, strength, immunity), the identification of 
the specific agent is of a significant importance for selecting 
the treatment, ensuring a rapid recovery and prevention of 
complications [19]. CT more often (42% of cases) is caused 
by infection with respiratory viruses (adenovirus, influenza 
virus, para-influenza virus, rhinovirus or respiratory syncytial 
virus), and in 30-40% of cases the cause is a bacterial infection 
[9, 10, 19]. Of all the microorganisms, the main ethiopatogenic 
agents in CT are ΒHSA (15 to 55.5% of cases), followed by 
Staphylococcus aureus [8, 12, 16, 40].
In the recent years, Staphylococcus aureus is considered the 
main pathogen responsible for CT [35]. According to the results 
of studies, the most common pathogen was Staphylococcus aure-
us (33%), followed by ΒHSA (30%), Streptococcus pneumoniae, 
Haemophilus influenzae, Escherichia coli, Pseudomonas aerugi-
nosa and Streptococcus viridans [35]. According to another study, 
Staphylococcus aureus (30.3%), Haemophilus influenzae (15.5%) 
and Streptococcus pyogenes (14.4%) were the most frequently 
isolated from patients with CA [9].
Although the cultures of tonsil core compared with iso-
lated cultures from superficial pharyngeal smears, provide a 
representative picture of the bacterial content in patients with 
CT and RT [15], in our study, the bacteriological analysis from 
the pharynx detected Streptococcus viridans in 56 (55.4%) 
cases, Staphylococcus aureus in 51 (50.5%) cases, Strepto-
coccus pyogenes in 45 (44.6%) cases, ΒHSA in 17 (16.8%) 
cases, Streptococcus pneumoniae in 8 (7.9%) and other flora 
in 22 (21.8%) cases. It should be underlined that different 
combinations of determined pathogen agents were found in 
most cases – in 87 (86.1%) patients.
Several researchers have tried to determine the genetic 
susceptibility and protective immune responses for PSRA and 
ARF [21, 25, 28, 30]. Validation of HLA associations observed 
in various populations of the world can contribute to the de-
velopment of cost-effective primary prevention strategies of 
these lesions [28]. It was observed a heterogeneity in terms of 
HLA alleles class I and II of susceptibility and/or protection in 
different studies in different geographical regions and ethnic 
groups, although associations with specific antigens have been 
reported [21, 25, 28, 30].
The study of major antigens did not find an association 
of HLA Class I (A, B and C) with ARF and RHD [23, 24, 31, 
42]. In other studies in patients with CT, including decom-
pensated CT, statistically significantly more often were found 
the antigens HLA-A2 and HLA-B12 [46]. Among children 
with mitral valve disease (MVD), compared to children in 
the control group, there was noted a significant increase in 
HLA-B5, and HLA-B49, HLA-B51 and HLA-B52 were found 
only in the control group and they have a protective role for 
these conditions [28].
Among mature people with ARF was also found a large 
increase, but statistically non-significant, of HLA-B5, com-
pared to the control group, a statistically significant increase 
in HLA-A10 and HLA-B35 [36].
In different populations, the frequency of HLA-A10, 
HLA-Aw33 and HLA-B35 antigens is significantly higher in 
adult patients with ARF and / or RHD (p<0.05 and P<0.01, 
respectively). The frequency of HLA-A10 and HLA-DRw11 
antigens in patients with RHD is significantly higher than 
in those with non-cardiac involvement (p<0.05 and p<0.01, 
respectively). On the other hand, the frequency of HLA-CH2 
antigen is significantly higher in patients without RHD com-
pared to those with RHD (p<0.05) [36].
The absence of a hereditary marker HLA class I in patients 
with RHD underlines the multiple and important factorial 
complexity in ARF pathogenesis, but does not exclude the role 
of genetic factors [42]. However, the susceptibility of RHD is 
mediated by HLA class II [43].
At patients in our study with chronic tonsillitis and articu-
lar syndrome, most frequently were diagnosed the following 
HLA Class A antigens (HLA-A2 – 44,6%, HLA-A28 – 41,6%, 
HLA-A24 – 23,8%, HLA-AX – 20,0%) and HLA class B 
(HLA-B35 – 31,7%, HLA-B44 – 17,8%, HLA-BY – 14,9%, 
HLA-B18 – 12,9%).
Therefore, the relationship between ARF and PSRA with 
HLA is contradictory and heterogeneous, and the sensitivity 
to ARF (and PSRA) is polygenic. Some diseases with poor 
initial association with the antigens HLA-A and HLA-B were 
found to have strong association with HLA-DR antigens. The 
strongest and most frequent association of ARF was proved 
to be with HLA-DR2, HLA-DR4 and HLA-DR7 phenotypes, 
and the PSRA – with HLA-DRB1 * 01 [14, 17, 23, 24, 39]. The 
relatively small number of patients tested and the differences 
in genetic background may partly explain the different results 
and the difficulty in the study of HLA alleles in identifying 
the same genetic susceptibility in different population. In 
order to understand completely the overall mechanism of 
genetic susceptibility, such studies need to be duplicated and 
validated in different ethnic populations, using a wider range 
of appropriate methods of analysis [28].
Currently, there are very few studies that estimate the role of 
the genetic system in the development of CT. Most studies pro-
vide additional information on genetic predisposition for MVD 
and protection genotypes in RHD. The results of several studies 
conducted in concordance to the hypothesis that the suscepti-
bility to RHD is genetically determined, have found a possible 
association with antigens HLA class II (HLA-DR) and a weak one 
with antigens HLA class I (HLA-A, HLA-B and HLA-C) [26]. 
Estimation of HLA class I antigens found a statistically signifi-
cant increase in HLA-B5 alleles in patients with RHD (p=0.03) 
compared to the control group, whereas the alleles HLA-B49 
(p=0.004) and the HLA- B52 (p=0.02) were found only in the 
control group [28]. A recent case-control study compared the 
frequency of CHM class II, HLA-DR alleles between patients with 
and without RHD. The authors found a low genetic susceptibility 
of HLA-DR1 with RHD, while HLA-DR11 was associated with 
an increased risk for RHD [20].
According to specialized literature, the impact of tonsillec-
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tonsillectomy reduces the symptoms of CT or RT in adults 
with remarkable effectiveness, resulting in a reduction in the 
number of episodes of sore throat and days with sore throat 
in children in the first year after surgery [48].
Conclusions
The study of the major antigens has not found an asso-
ciation of HLA class I (A, B) with ARF and rheumatic heart 
disease (RHD).
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